Merck has announced that the antagonist of the calcitonin gene-related peptide (CGRP) receptor telcagepant has met the primary end points in two Phase III trials to treat migraine, which is ...

It's called CGRP-targeted therapy, and the FDA has approved the first drugs in this new class of treatments. I've been involved in headache medicine for 30 years, and the CGRP-targeted therapies ...

If approved, AJOVY would be the only calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in pediatric patients, helping to address ...

Ligustroside also suppressed the nuclear protein expression of MITF, β-catenin, and p-CREB, and decreased immunofluorescence intensity of nuclear MITF. Ligustroside derived from Ligustrum ...